Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionQube Research & Technologies Ltd
Latest Disclosed Ownership3,998 shares
Latest Disclosed Value $ 1,785,267
Qube Research & Technologies Ltd ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Qube Research & Technologies Ltd filed a 13F-HR form disclosing ownership of 3,998 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $1,785,267 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 0 shares of Vertex Pharmaceuticals Incorporated. The current value of the position is $1,712,503 USD.

Qube Research & Technologies Ltd has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 8,200 of underlying shares valued at $3,661,628 USD and put options representing 10,200 of underlying shares valued at $4,554,708 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,998 3,998 1,785 0.0020
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -51,382 -100.00 0 -100.00
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 51,382 45,701 804.45 20,123 695.69 0.0208
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,681 -28,865 -83.56 2,529 -84.90 0.0026
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 34,546 34,546 16,749 0.0194
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -131,156 -100.00 0 -100.00
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 131,156 -322,217 -71.07 60,998 -71.30 0.0899
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 453,373 -105,163 -18.83 212,505 -8.98 0.3359
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 558,536 93,511 20.11 233,474 23.39 0.3701
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 465,025 45,916 10.96 189,214 29.83 0.3683
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 419,109 339,462 426.21 145,741 419.98 0.3808
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 79,647 79,647 28,029 0.1019
2023-05-15 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -427,529 -100.00 0 -100.00
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 427,529 330,619 341.16 123,462 340.00 0.6609
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 96,910 96,910 28,059 0.1671
2022-02-10 2021-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 0 -43,583 -100.00 0 -100.00
2022-02-01 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -43,583 0
2021-11-12 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 43,583 43,583 7,906 0.0992
2021-08-13 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -28,845 -100.00 0 -100.00
2021-05-14 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 28,845 28,845 6,199 0.0983
2021-02-16 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -20,293 -100.00 0 -100.00
2020-11-12 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 20,293 5,720 39.25 5,522 30.51 0.0788
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,573 10,665 272.90 4,231 354.95 0.0621
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,908 -9,901 -71.70 930 -69.24 0.0382
2020-02-13 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 13,809 13,809 3,023 0.0949
2019-08-02 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -9,494 -100.00 0 -100.00
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,494 9,494 1,746 0.2306
2019-02-14 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -7,098 -100.00 0 -100.00
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,098 6,209 698.43 1,368 805.96 0.1819
2018-08-15 2018-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 889 -472 -34.68 151 -31.67 0.0953
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 889 -472 151
2018-05-14 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,361 1,361 221 0.0850
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM Call 8,200 -67.33 3,662 -67.83 n/a n/a n/a
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM Call 25,100 35.68 11,379 57.06 n/a n/a n/a
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM Call 18,500 60.87 7,245 41.53 n/a n/a n/a
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM Call 11,500 447.62 5,120 402.85 n/a n/a n/a
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM Call 2,100 -91.53 1,018 -89.81 n/a n/a n/a
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM Call 24,800 -50.50 9,987 -57.14 n/a n/a n/a
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM Call 50,100 16,600.00 23,301 16,542.86 n/a n/a n/a
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM Call 300 141 n/a n/a n/a
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM Call 9,600 3,338 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM Put 10,200 -60.92 4,555 -61.51 n/a n/a n/a
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM Put 26,100 52.63 11,833 76.68 n/a n/a n/a
2025-11-14 2025-09-30 13F VERTEX PHARMACEUTICALS COM Put 17,100 -16.99 6,697 -26.98 n/a n/a n/a
2025-08-14 2025-06-30 13F VERTEX PHARMACEUTICALS COM Put 20,600 103.96 9,171 87.32 n/a n/a n/a
2025-05-15 2025-03-31 13F VERTEX PHARMACEUTICALS COM Put 10,100 -73.83 4,897 -68.50 n/a n/a n/a
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM Put 38,600 -83.24 15,544 -85.49 n/a n/a n/a
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM Put 230,300 52.72 107,108 51.53 n/a n/a n/a
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM Put 150,800 70,683 n/a n/a n/a
2024-05-14 2024-03-31 13F VERTEX PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-02-13 2023-12-31 13F VERTEX PHARMACEUTICALS COM Put 26,000 -24.86 10,579 -12.07 n/a n/a n/a
2023-11-13 2023-09-30 13F VERTEX PHARMACEUTICALS COM Put 34,600 12,032 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.